HEPTANOIN, TRI-

Epilepsy

University of Texas Southwestern Medical CenterSmall moleculePhase 2Dormant

B

58/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 49/ 100
Competitive Position: 73/ 100

Competitive context

77 Active assets in the Epilepsy cohort.

Asset / Sponsor	Phase	Rating
Topamax SK Life Science, Inc.	Phase 4	BBB
Eslicarbazepine Acetate Bial - Portela C S.A.	Phase 4	BBB
Keppra Beijing Tiantan Hospital	Phase 4	BBB
Carbamazepine Assistance Publique - Hôpitaux de Paris	Phase 4	BBB
Topamax Université de Sherbrooke	Phase 4	BBB

View all 50 →

Same molecule, other indications

HEPTANOIN, TRI- is also rated in:

GLUT1 deficiency syndromeDormant

BB

Indicative ·

69 / 100

Glucose Transporter Protein Type 1 Deficiency SyndromeDormant

BB

Indicative ·

69 / 100

encephalopathy due to GLUT1 deficiencyDormant

BB

Indicative ·

64 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.